Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An 82-year-old female was diagnosed as having 5q- syndrome accompanied by basophilia, eosinophilia and thrombocytosis. Since cytogenetic abnormalities other than 5q- were also detected, she was considered to be type B of 5q- syndrome. According to the FAB classification a diagnosis of refractory anemia with excess of blasts (RAEB) was made. She was treated with recombinant interferon alpha 2b, because peripheral blood findings resembled those of chronic myelogenous leukemia. Interferon was effective, and resulted in disappearance of peripheral blasts, normalization of platelet numbers, and improvement of basophilia. These changes were interferon-dependent. After 1 year, cytogenetic studies revealed that about 2/3 of metaphases showed normal karyotype. Twenty months after diagnosis, myeloid blastic crisis occurred and eventually the patient died. However, treatment with interferon in this case might support the usefulness of the drugs for this kind of disease.
 ...
PMID:[Hematologic improvement by alpha-interferon in a case of the 5q- syndrome with basophilia and eosinophilia]. 771 73

Fourteen patients with relapsed refractory hematologic malignancies including 3 patients with AML, 7 with acute blastic CML and 4 patients with NHL were treated with a combination of cytosine arabinoside 100 mg/m2/day plus interferon alpha 2b 10 U/m2/day given by continuous infusion for 7-10 days. Therapy was based on in vitro synergy between the two drugs. Two patients with AML achieved CR. In addition 4/7 (57%) patients with blastic-CML and 1/4 (24%) with NHL achieved CR. Five patients achieved PR. The combination of cytosine arabinoside plus interferon appears to have significant clinical activity in these heavily pretreated patients. Treatment was well tolerated with the major toxicity being transient hematologic suppression.
 ...
PMID:Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma. 2157 79